CL2022000938A1 - Casete de transferencia de aav - Google Patents
Casete de transferencia de aavInfo
- Publication number
- CL2022000938A1 CL2022000938A1 CL2022000938A CL2022000938A CL2022000938A1 CL 2022000938 A1 CL2022000938 A1 CL 2022000938A1 CL 2022000938 A CL2022000938 A CL 2022000938A CL 2022000938 A CL2022000938 A CL 2022000938A CL 2022000938 A1 CL2022000938 A1 CL 2022000938A1
- Authority
- CL
- Chile
- Prior art keywords
- aav transfer
- transfer cassette
- plasmids
- cassettes
- npc1
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención describe casetes de transferencia de AAV y plásmidos que se utilizan en la producción de vectores virales adenoasociados recombinantes (rAAV). Los casetes y plásmidos divulgados comprenden uno o más transgenes que tienen eficacia terapéutica en la mejora, tratamiento y/o prevención de una o más enfermedades o trastornos, como la enfermedad de Niemann-Pick, Tipo C1 (NPC1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962916749P | 2019-10-17 | 2019-10-17 | |
US201962923253P | 2019-10-18 | 2019-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000938A1 true CL2022000938A1 (es) | 2023-01-20 |
Family
ID=73344131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000938A CL2022000938A1 (es) | 2019-10-17 | 2022-04-13 | Casete de transferencia de aav |
Country Status (14)
Country | Link |
---|---|
US (2) | US20240131185A1 (es) |
EP (1) | EP4045524A1 (es) |
JP (1) | JP2022551744A (es) |
KR (1) | KR20220083708A (es) |
CN (1) | CN114585743A (es) |
AU (1) | AU2020367825A1 (es) |
BR (1) | BR112022006946A2 (es) |
CA (1) | CA3157702A1 (es) |
CL (1) | CL2022000938A1 (es) |
CO (1) | CO2022004652A2 (es) |
IL (1) | IL292264A (es) |
MX (1) | MX2022004353A (es) |
TW (1) | TW202128737A (es) |
WO (1) | WO2021076911A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3774854A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
TW202102525A (zh) | 2019-03-21 | 2021-01-16 | 美商史崔德生物公司 | 重組腺相關病毒載體 |
MX2022004352A (es) | 2019-10-17 | 2022-07-19 | Stridebio Inc | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c. |
WO2023221942A1 (en) * | 2022-05-16 | 2023-11-23 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant aav vectors for treating glutaric aciduria type i |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016164642A1 (en) * | 2015-04-08 | 2016-10-13 | The United States Of America, As Represented By The Secretary Of Health And Human Services | Viral gene therapy as treatment for cholesterol storage disease or disorder |
US11020443B2 (en) * | 2015-04-23 | 2021-06-01 | University Of Massachusetts | Modulation of AAV vector transgene expression |
EP3387137B1 (en) * | 2015-12-11 | 2021-02-03 | California Institute of Technology | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) |
US20200255859A1 (en) * | 2017-07-31 | 2020-08-13 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
-
2020
- 2020-10-15 US US17/769,615 patent/US20240131185A1/en active Pending
- 2020-10-16 US US17/072,637 patent/US20210128652A1/en active Pending
- 2020-10-16 CA CA3157702A patent/CA3157702A1/en active Pending
- 2020-10-16 MX MX2022004353A patent/MX2022004353A/es unknown
- 2020-10-16 KR KR1020227012835A patent/KR20220083708A/ko unknown
- 2020-10-16 TW TW109136019A patent/TW202128737A/zh unknown
- 2020-10-16 CN CN202080073371.6A patent/CN114585743A/zh active Pending
- 2020-10-16 JP JP2022522332A patent/JP2022551744A/ja active Pending
- 2020-10-16 WO PCT/US2020/056015 patent/WO2021076911A1/en active Application Filing
- 2020-10-16 EP EP20804714.2A patent/EP4045524A1/en active Pending
- 2020-10-16 BR BR112022006946A patent/BR112022006946A2/pt unknown
- 2020-10-16 AU AU2020367825A patent/AU2020367825A1/en active Pending
-
2022
- 2022-04-12 CO CONC2022/0004652A patent/CO2022004652A2/es unknown
- 2022-04-13 IL IL292264A patent/IL292264A/en unknown
- 2022-04-13 CL CL2022000938A patent/CL2022000938A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022004652A2 (es) | 2022-04-29 |
TW202128737A (zh) | 2021-08-01 |
BR112022006946A2 (pt) | 2022-08-23 |
US20210128652A1 (en) | 2021-05-06 |
US20240131185A1 (en) | 2024-04-25 |
EP4045524A1 (en) | 2022-08-24 |
KR20220083708A (ko) | 2022-06-20 |
CN114585743A (zh) | 2022-06-03 |
WO2021076911A1 (en) | 2021-04-22 |
AU2020367825A1 (en) | 2022-05-12 |
CA3157702A1 (en) | 2021-04-22 |
JP2022551744A (ja) | 2022-12-13 |
MX2022004353A (es) | 2022-07-19 |
IL292264A (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000938A1 (es) | Casete de transferencia de aav | |
CO2021008120A2 (es) | Vectores virales recombinantes y ácidos nucleicos para producirlos | |
CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
PE20190129A1 (es) | Capsides variantes de virus adenoasociados y metodos de uso de estas | |
CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
CO2018000134A2 (es) | Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos | |
WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
BR112016025263A2 (pt) | vetores de avv para terapia genética retiniana e do snc | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
AR099837A1 (es) | Terapia génica para la retinitis pigmentaria | |
MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
MX2021014338A (es) | Particulas virales modificadas y usos de estas. | |
CL2022000939A1 (es) | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c | |
BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
EP4055174A4 (en) | TRANSGENIC CASSETTES, AAV VECTORS AND AAV VIRAL VECTORS FOR EXPRESSION OF THE SLC6A1 GENE WITH OPTIMIZED HUMAN CODONS | |
CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
CO2022001833A2 (es) | Proteína vp1 modificada aislada de la cápside del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en la misma. | |
AR120252A1 (es) | Casete de transferencia de aav | |
EP3843791A4 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF BEST'S DISEASE | |
EP4022073A4 (en) | ADENO-ASSOCIATED VIRAL VECTORS TO CROSS THE HUMAN BLOOD-BRAIN BARRIER | |
BR112017022621A2 (pt) | liberação do gene de smad7 como uma substância terapêutica | |
UY38238A (es) | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
NZ764033A (en) | Aav vectors for retinal and cns gene therapy | |
AR122285A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad de sanfilippo y otros trastornos |